PRESS RELEASE published on 02/28/2025 at 07:30, 1 year 7 months ago Inside Information / Other news releases ABIONYX renews commitment to treat LCAT Deficiency (Norum's disease) and provides updates on advances, including submission of Marketing Authorization Application and Orphan Disease Designation ABIONYX LCAT Deficiency Rare Disease Day Marketing Authorization Application Orphan Disease Designation
BRIEF published on 02/27/2025 at 19:25, 1 year 7 months ago ABIONYX Pharma Reports Stable Revenue and Cash Position for 2024 2024 Financial Results Innovative Therapies ABIONYX Pharma Compassionate Access CRO Industry
PRESS RELEASE published on 02/27/2025 at 19:20, 1 year 7 months ago Inside Information / Information on annual revenues ABIONYX Pharma reports €4.6m revenue and €3.2m cash at the end of Q4 2024. Details on business activities and financial performance included Revenue Cash Position Financial Update Biopharma ABIONYX Pharma
BRIEF published on 02/20/2025 at 07:35, 1 year 7 months ago ABIONYX Pharma receives €8.7 million in support for its sepsis project Financial Support France 2030 ABIONYX Pharma Sepsis Biomedicine
BRIEF published on 12/11/2024 at 12:16, 1 year 9 months ago Threshold crossing by the CDC in ABIONYX PHARMA Voting Rights CDC Threshold Crossing ABIONYX Pharma Bpifrance Participations
BRIEF published on 12/11/2024 at 12:13, 1 year 9 months ago Threshold crossing by Bpifrance in ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX
BRIEF published on 12/10/2024 at 10:51, 1 year 9 months ago Threshold crossing by Cyrille Tupin at ABIONYX PHARMA Voting Rights Actions Threshold Crossing ABIONYX Pharma Cyrille Tupin
BRIEF published on 11/14/2024 at 19:05, 1 year 10 months ago ABIONYX Pharma: Third quarter 2024 financial report Biotechnology Treasury Turnover Q3 2024 ABIONYX Pharma
PRESS RELEASE published on 11/14/2024 at 19:00, 1 year 10 months ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
BRIEF published on 10/24/2024 at 19:35, 1 year 11 months ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
Published on 10/08/2026 at 12:00, 58 minutes ago Zomedica Announces "Fourth Friday at Four" Webinar on October 23, 2026: Zomedica's Clinical Program: How Evidence Drives Adoption
Published on 10/08/2026 at 11:35, 1 hour 23 minutes ago Battery X Metals Announces Corporate Awareness Agreement
Published on 10/08/2026 at 11:00, 1 hour 58 minutes ago Silver Range Resources Ltd. Options Alamo and Sand Springs to Resilience Minerals Limited
Published on 10/08/2026 at 11:00, 1 hour 58 minutes ago Meta Critical Minerals Initiates Maiden Drill Program At Table Mountain High-Purity Silica Project, British Columbia
Published on 10/07/2026 at 23:30, 13 hours 28 minutes ago Algo Grande Copper Core Testing Shows Mineralized Skarn is Denser and More Chargeable Than Host Rocks; Ground Gravity Survey to Begin at Adelita
Published on 10/08/2026 at 11:35, 1 hour 22 minutes ago ZEISS acquires Ceres Holographics to accelerate holography industrialization
Published on 10/08/2026 at 11:13, 1 hour 44 minutes ago InTiCa Systems SE completes segment change to Scale at the Frankfurt Stock Exchange effective October 14, 2026
Published on 10/08/2026 at 11:00, 1 hour 58 minutes ago ABB Ltd: ABB share buybacks - October 1, 2026 - October 7, 2026
Published on 10/08/2026 at 10:44, 2 hours 14 minutes ago Stable First-Half Performance in 2026 – Operating Platform Strengthened for Further Growth
Published on 10/08/2026 at 10:40, 2 hours 17 minutes ago Avalara Helps Global Businesses Move Faster as Tax and Compliance Complexity Accelerates
Published on 10/07/2026 at 18:19, 18 hours 38 minutes ago Outstanding shares and voting rights statement at 30 September 2026
Published on 10/07/2026 at 17:45, 19 hours 13 minutes ago Availability of the Pre-Q3 2026 Sales Communication
Published on 10/07/2026 at 15:54, 21 hours 3 minutes ago Disclosure of Share Capital and Voting Rights as of September 30, 2026
Published on 10/07/2026 at 08:15, 1 day 4 hours ago EURAZEO TO ACQUIRE MIYA WATER, A GLOBAL SPECIALIST IN EFFICIENT WATER MANAGEMENT SOLUTIONS
